ΒιΆΉ΄«Γ½

Meeting Coverage

IASLC Video Pearls

Video Pearls from the International Association for the Study of Lung Cancer

What's Left for Nivolumab to Prove in Stage IIIA NSCLC?

Nicholas Rohs, MD, discusses the results from the NADIM II trial

image

Latest IASLC Video Pearls Meeting Coverage

OS Promising for Adjuvant Atezolizumab in PD-L1-Positive NSCLC

Nicholas Rohs, MD, discusses updated results from the IMpower010 trial

September 6, 2022
Sublobar Resection the 'New Standard of Care' for Small Lung Cancers

"This is something that we've been hoping for for a long time," says Nicholas Rohs

August 29, 2022
Trials Affirm Value of Immunotherapy in Resectable NSCLC

James Stevenson, MD, discusses the NADIM II and IMpower010 findings

August 22, 2022
Lurbinectedin-Doxorubicin Combo Misses Survival Mark in SCLC

Luis Paz-Ares discusses ATLANTIS study results in challenging disease

October 7, 2021
Atezolizumab Regimen Safe in Resectable Mesothelioma

Boris Sepesi lays out next steps following feasibility study

September 30, 2021
Immunotherapy-Chemo Offers Survival Advantage in Low PD-L1 NSCLC

Melissa Johnson, MD, breaks down the clinical significance of the findings

September 23, 2021

Latest Oncology/Hematology Meeting Coverage